Request Demo

Last update 09 May 2025

Certolizumab Pegol

Last update 09 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Fab fragment

Synonyms

AutoClicks-Prefilled-Pen, Certolizumab, Certolizumab Pegol (Genetical Recombination)

+ [12]

Target

TNF-α

Action

inhibitors

Mechanism

TNF-α inhibitors(Tumor necrosis factor α inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesDigestive System Disorders+ [5]

Active Indication

Erythrodermic psoriasisPsoriasis vulgarisPustular psoriasis+ [13]

Inactive Indication

Brain InjuriesColitis, UlcerativeCrohn's disease, active moderate+ [6]

Originator Organization

UCB SA

Active Organization

UCB Pharma GmbHUCB BioSciences GmbH

UCB Japan Co. Ltd.

+ [5]

Inactive Organization

UCB Pharma Ltd.

Otsuka Pharmaceutical Co., Ltd.Korea Otsuka Pharmaceutical Co., Ltd.

+ [1]

License Organization

Ferring Pharmaceuticals SA

Dermira, Inc.

UCB SA

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (22 Apr 2008),

Crohn Disease

RegulationPriority Review (China)

Structure/Sequence

Sequence Code 7540H

Source: *****

Sequence Code 99012L

Source: *****

119

Clinical Trials associated with Certolizumab Pegol

NCT05930613

/ RecruitingPhase 3IIT

Efficacy of Certolizumab in Women With Unexplained Recurrent Implantation Failure: a Double-blind Randomized Controlled Trial

Recurrent implantation failure (RIF), defined as the absence of clinical pregnancy after the transfer of three good-quality embryos, concerns up to 40% of IVF couples and is associated with a low success rate. The causes remain unexplained in over 50% of cases.
Various dysimmune changes (related to immune T cells profiles, pro-inflammatory cytokines levels) have been described in unexplained RIF as compared to fertile controls, and it has been estimated that such dysimmunity may occur in 50% of unexplained RIFs. Previous data on a benefit of general immune modulation by steroids or immunoglobulins are heterogenous and failed to demonstrate clinically significant benefit. The proinflammatory cytokine Tumor Necrosis Factor (TNF) α participates in the regulation of the immune balance of the endometrium, its peripheral blood and endometrial concentrations are increased in RIF patients as compared to fertile controls. In 2009, a pilot placebo controlled study showed that TNF-α antagonist treatment allowed a 56% live birth rate (versus 13% in controls) in 13 women with unexplained RIF. Due to the lack of maternal and fetal tolerance data, TNF-α antagonists were not further evaluated. Today, safety data issued from 1200 pregnancies are reassuring allowing the use of TNF-α antagonists during pregnancy (www.lecrat.org). In addition the TNF-α antagonist certolizumab does not cross the placental barrier.
We hypothesize that certolizumab may improve clinical pregnancy rates in women with unexplained RIF with a good safety profile.

Start Date30 Nov 2023

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

NCT06028438

/ CompletedPhase 2

A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of Concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis Despite Prior Treatment With Advanced Therapies (bDMARD or tsDMARD)

The purpose of this study is to evaluate the efficacy of combination therapy with nipocalimab and certolizumab compared to certolizumab monotherapy.

Start Date15 Aug 2023

Sponsor / Collaborator

Janssen Research & Development LLC

NCT05115903

/ Active, not recruitingPhase 4IIT

A Prospective, Randomized Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis

Current evidence on tapering of tumor necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) is still hampered by heterogeneity in tapering regimens, selection and performance biases, and lack of data on optimized treatment dosing strategies especially in real-world clinical settings. This study aims to contribute to the ongoing investigation of disease-activity-guided tapering of TNFi in axSpA in the form of a prospective, randomized controlled trial.

Start Date01 Dec 2021

Sponsor / Collaborator

University Health Network

100 Clinical Results associated with Certolizumab Pegol

100 Translational Medicine associated with Certolizumab Pegol

100 Patents (Medical) associated with Certolizumab Pegol

1,985

Literatures (Medical) associated with Certolizumab Pegol

01 May 2025·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

The use of aptamers as therapeutic inhibitors and biosensors of TNF-alpha

Review

Author: Sahebkar, Amirhossein ; Kesharwani, Prashant ; Abianeh, Hossein Samiei

Tumor necrosis factor-alpha (TNF-α) is a pivotal cytokine in the pathogenesis of numerous inflammatory and autoimmune diseases. Precise and sensitive detection of TNF-α is essential for both clinical applications and research endeavors. In the realm of cytokine detection, particularly TNF-α, the development of highly sensitive and specific biosensors has become a focal point. The biosensing landscape encompasses a variety of biorecognition elements, each with its unique set of characteristics. TNF inhibitors come with a significant price tag and, notably, do not yield positive responses in all patients. Despite the availability of numerous FDA-approved biologic agents (e.g., infliximab, adalimumab, certolizumab pegol, etc.) and monoclonal antibodies (e.g., adalimumab) targeting TNF-α, aptamers tailored for blocking TNF-α activities have yet to receive approval. Aptamers have rapidly gained recognition as readily available, versatile, and highly effective molecular tools for both therapeutic and diagnostic purposes in the context of TNF-alpha. In this manuscript, we explore the potential of short single-stranded DNA or RNA sequences known as aptamers as biorecognition elements in biosensors designed for the detection of TNF-α. We delve into the progress made in the development of aptamer-based TNF-α inhibitors and shed light on successful studies in this burgeoning field.

18 Apr 2025·ACS Chemical Biology

Noninvasive Bioluminescence Imaging of Serum Albumins in Living Mice

Article

Author: Maki, Shojiro A. ; Kim, Sung-Bae ; Paulmurugan, Ramasamy ; Furuta, Tadaomi ; Kamiya, Genta ; Kitada, Nobuo ; Natarajan, Arutselvan ; Thangudu, Suresh

Bioluminescence (BL) is an emerging optical readout that has been extensively used in various bioassays and molecular imaging systems. In this study, we present the bioanalytical application of marine luciferins as an excellent optical indicator for noninvasive imaging of serum albumins. We synthesized 30 kinds of regioisomeric coelenterazine (CTZ) analogs and investigated their specificities for major serum proteins from various species. The results found that some of the CTZ analogs exhibited surprisingly specific optical signals upon binding with the serum albumins. These CTZ analogs showed diverse emission spectra ranging from 495 to 558 nm according to the albumin species used acting as pseudoluciferases. The selective albumin indicators, TS1 and TS2, exhibited long and linear dose-response curves and were sensitive enough to determine clinically normal and abnormal (microalbuminuria) ranges of albumins in saliva and urine. The sensitivity of this assay is superior to that of the conventional Bromocresol purple (BCP) method. We further demonstrated the advantages of the albumin indicators through noninvasive imaging of liver-albumin in vivo in living mice. The in vivo and ex vivo imaging results confirmed that the CTZ analog TS2 can sensitively image the liver-albumin in vivo with high signal-to-background ratio. This study paves a new way to make use of CTZ analogs for noninvasive albumin imaging and conceptualizes the pseudoluciferase-based imaging. The distinct in vivo imaging of serum albumins can potentially aid clinicians in providing insight into patients' liver function and other vital factors needed for whole-body homeostasis.

10 Apr 2025·Crohns & Colitis 360

Racial Disparities in Utilization of Medications and Disease Outcomes in Inflammatory Bowel Disease Patients

Article

Author: Regueiro, Miguel ; Alsabbagh Alchirazi, Khaled ; Hamid, Osama ; Azzouz, Nour ; Alkhayyat, Motasem ; Qapaja, Thabet ; Aldiabat, Mohammad

Abstract:

Background:

Although traditionally associated with White European ancestry, inflammatory bowel disease (IBD) has increased among different races and ethnicities. Large studies conducted in the United States and Canada have identified more complex disease phenotypes among Black patients. Our study aimed to investigate disparities in IBD treatments and outcomes between Black and White patients in the United States.

Methods:

Using the TriNetX database, adult IBD patients were divided into 2 groups based on race: Black and White patients with IBD, Crohn’s disease (CD), or ulcerative colitis (UC). Medical therapy and disease outcomes were evaluated in both groups with 1:1 propensity-score matching. Methodologic limitations include the potential for missing data, lack of information on socioeconomic strata, and patient-level medication coverage plans.

Results:

In comparison to White patients, Black patients with CD were less likely to receive advanced therapies; Adalimumab (adjusted odds ratio- aOR 0.89), Certolizumab (0.81), Vedolizumab (0.66), Ustekinumab (0.82), or Tofacitinib (0.58). Black patients with UC were less likely to receive advanced therapies; Adalimumab (0.83), Golimumab (0.62), Vedolizumab (0.69), Ustekinumab (0.73), or Tofacitinib (0.55). Black patients with IBD were at higher odds of utilizing corticosteroids (CD 1.18 and UC 1.20) and opioids (CD 1.26 and UC 1.09). Black patients with CD had higher rates of hospitalization (1.35) and perianal abscess (1.56), perianal fistula (1.28), and intestinal fistula (1.38). Black patients with UC had higher rates of hospitalization (1.29), Clostridioides difficile infection (1.11), and toxic megacolon (1.34).

Conclusions:

There were racial disparities in IBD medical therapy and disease outcomes. Black IBD patients had lower treatment with advanced therapies, higher opioid and corticosteroid use, and higher IBD-related complications.

News (Medical) associated with Certolizumab Pegol

20 Mar 2025

·pipelinereview.com

Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

REYKJAVIK, Iceland and STOCKHOLM, Sweden I March 20, 2025 I Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane Biopharma AB’s (“Xbrane”) R&D operations and a biosimilar candidate (the “Acquisition”), further expanding Alvotech’s development capabilities, and establishing a footprint in the Swedish life science sector. The Acquisition includes Xbrane’s R&D operations based in Campus Solna, at the Karolinska Institute outside Stockholm, Sweden, as well as the biosimilar candidate XB003, referencing Cimzia® (certolizumab pegol). Xbrane retains other pre-clinical assets and will focus on the commercialization of this portfolio. Alvotech also announced that it intends to explore the possibility of a listing of Swedish Depository Receipts (SDR), equity share equivalents, on Nasdaq Stockholm, in the future. The acquisition in brief “Alvotech has a best-in-class biosimilars manufacturing site in Iceland, both for drug substance and drug products. At the same time, our strong in-house R&D capabilities have put Alvotech in a leading position among pure play biosimilar companies in terms of the market value of our product pipeline. This acquisition will further expand Alvotech’s development capacity, allowing our commercial network of 19 leading commercial partners worldwide to continue increasing patient access to quality biologics,” said Robert Wessman, founder, Chairman and CEO of Alvotech. “Furthermore, we will establish a strong presence for Alvotech in the Swedish life science sector, which rivals the U.S. in this field. It will allow Alvotech to attract new talent, create opportunities for scientific collaboration, and support our growth. This is yet another milestone for Alvotech in establishing us as a leader in biosimilars development and production globally.” “With this transaction Xbrane is significantly strengthening its financial position and retains over 75% of the competitively adjusted addressable market of the portfolio including Ximluci (Lucentis biosimilar candidate) currently being approved and sold in Europe as well as Xdivane (Opdivo biosimilar candidate), recently partnered with Intas. Xbrane will, with a more lean and flexible organization after the transaction, be better equipped to fully focus on realizing the full value of Ximluci and Xdivane with the ambition to generate meaningful royalties/profit sharing from these programs in the years to come,” said Martin Åmark, CEO of Xbrane. Headquartered in Reykjavik, Iceland, Alvotech’s shares are listed on Nasdaq Iceland and Nasdaq US. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Since 2013, Alvotech has invested about $1.9 billion in a purpose-built biosimilars R&D and manufacturing platform, established commercial partnerships with 19 leading companies in over 90 of the largest global markets and developed one of the most valuable portfolios in the biosimilars industry. Advisors DNB Carnegie is acting as financial advisor to Alvotech in connection with the Acquisition. Cirio and Westerberg are legal advisors to Alvotech in connection with the Acquisition. About Alvotech Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Two biosimilars, to Humira® (adalimumab) and Stelara® (ustekinumab) are already approved and marketed in multiple global markets. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit https://www.alvotech.com . None of the information on the Alvotech website shall be deemed part of this press release. For more information, please visit our investor portal , and our website or follow us on social media on LinkedIn , Facebook , Instagram , and YouTube . SOURCE: Alvotech

AcquisitionDrug ApprovalBiosimilar

29 Oct 2024

·www.prnewswire.com

Genascence Appoints Jeymi Tambiah as Chief Medical Officer

—Accomplished physician-scientist with more than 15 years' biopharmaceutical industry experience in medical affairs, clinical development, and drug development —Visionary leader skilled at leveraging scientific and clinical expertise to build innovative first-in-class therapeutic programs in areas of osteoarthritis, immunology, oncology, and neuroscience PALO ALTO, Calif., Oct. 29, 2024 /PRNewswire/ -- Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced the appointment of Jeymi Tambiah, MBChB, FRCS, MS, FAPCR, MFPM(Dis) as its chief medical officer. Dr. Tambiah is an accomplished physician-scientist with more than 15 years' biopharmaceutical industry experience creating and leading strategies for medical affairs, clinical development, and drug development programs. He also brings deep experience in translational medicine, commercialization, and health outcomes research to Genascence. Continue Reading Jeymi Tambiah, Chief Medical Officer, Genascence "Jeymi is a visionary leader skilled at leveraging scientific and clinical expertise to build innovative first-in-class therapeutic programs in the areas of osteoarthritis, immunology, oncology, and neuroscience and I am excited to welcome him to Genascence as our chief medical offer," said Thomas Chalberg, Ph.D., founder and CEO of Genascence. "His experience includes all phases of drug development from bench through Phase 1-4 clinical studies and building elite high performance medical affairs teams. Jeymi's development and research expertise, particularly within the osteoarthritis research community, will be invaluable as we execute on our strategy to bring gene therapy to people suffering from prevalent musculoskeletal diseases." "Genascence is a company that is transforming how we treat debilitating musculoskeletal diseases like osteoarthritis by pioneering the development of gene therapy," said Dr. Tambiah. "I am thrilled to join this outstanding team under Tom's leadership and apply my knowledge and experience to advance our clinical program so that we can bring potentially curative therapies to patients in desperate need of better treatments." Before joining Genascence, Jeymi was senior vice president of clinical development and external innovation at Biosplice Therapeutics, a start-up biotech developing molecules modulating mRNA splicing in oncology, arthritis, and neurodegenerative diseases, where he was primarily responsible for clinical development, medical affairs, and external thoughtleader and scientific partnerships. Previously, Jeymi worked for UCB Pharma in various roles of increasing leadership within medical affairs, launching the TNF-inhibitor certolizumab pegol within the European Union, U.K., and U.S. across multiple immunology indications. Before his move into pharma, Jeymi trained and practiced in cardiothoracic surgery at Guys' and St. Thomas' Hospitals in London. Jeymi is very active in the osteoarthritis research community, with numerous research awards and publications, holding many committee appointments, and regularly presenting at international conferences. He is the North American representative for the Faculty of Pharmaceutical Medicine UK, and in this role is dedicated to supporting the education and mentoring of physicians in drug development. Jeymi earned his medical degree from the University of Manchester, UK, a doctorate degree in vascular biology from Imperial College London where he was a Wellcome Research Fellow, and a BSc (Hons) in medical science from the University of St. Andrews, UK. He is a fellow of the Royal College of Surgeons of England and Edinburgh, a member of Faculty of Pharmaceutical Physicians UK by Distinction, and a fellow of the Academy of Physicians in Clinical Research. About Genascence Corporation Genascence, a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, is developing life-changing treatments for highly prevalent conditions affecting millions of people. The company was founded in 2017 with technology licensed from three leading U.S. research institutions: Mayo Clinic, University of Florida, and NYU Langone Health. Headquartered in Palo Alto, California, Genascence's founders and leadership team have deep experience in the design, development, and manufacturing of successful gene therapies and biological medicines. For more information, please visit . SOURCE Genascence WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Executive ChangeGene Therapy

22 Jul 2024

·healthcare-digital.com

Research Breakthrough Promises New Lupus Treatments

The purple ribbon denotes World Lupus Day, May 10. As study of patients with lupus uncovers a root cause of the condition we take a deeper look at the autoimmune disease and how it is currently treated A study of patients with lupus has uncovered a root cause of the disease that may eventually lead to new treatments, researchers reported in a study published in Nature. The immune disorder affects more than 1.5 million people in the US alone, and damages skin, joints, the kidneys, the brain and other organs. Comparing blood samples from 19 patients suffering from lupus with healthy people, researchers found that the patients had an imbalance in immune-system cells called ‘T cells’. There was reduced production of T cells that aid in healing, and increased production of T cells that produce autoantibodies to attack healthy cells. In the wake of the study, we take a look at lupus – at its effects and the available treatments. What is lupus? Lupus is an autoimmune disease that causes the body's immune system to attack its own tissues and organs. This condition can affect various parts of the body, including skin, joints, kidneys, brain, heart and lungs. Diagnosis can be complex, as symptoms often mimic those of other ailments. Treatment options for lupus depend on the severity of symptoms and which organs are affected. The cause of lupus remains unknown, but researchers believe it involves a combination of genetic and environmental factors. Women are more likely to develop lupus than men, and it is more prevalent in certain ethnic groups. Patients with lupus are advised to protect themselves from sun exposure, as ultraviolet light can trigger flares in some individuals. How is lupus treated? Medications include anti-inflammatory drugs, antimalarial drugs and immunosuppressants. Research has shown antimalarial drugs such as hydroxychloroquine and chloroquine can decrease the frequency and severity of lupus flare-ups. They work by modulating the immune system, which is overactive in lupus patients. This helps reduce inflammation and pain, particularly in the skin and joints. These medications also help protect the heart, and are thought to lower the risk of blood clots in lupus patients. This is significant as individuals with lupus have an increased risk of cardiovascular complications. Antimalarials are used in combination with immunosuppressants for more severe cases. Immunosuppressants are used to treat lupus because the condition results in the body's immune system mistakenly attacking healthy tissue, causing inflammation and damage to organs including the kidneys, heart and lungs. Common immunosuppressants used in lupus treatment include methotrexate, azathioprine, mycophenolate mofetil, and cyclophosphamide. These can be administered orally or intravenously, depending on the specific drug and the patient's condition. The use of immunosuppressants carries risks, as a suppressed immune system makes the patient more susceptible to infections. Companies that specialise in lupus medicines Medications used to treat lupus include anti-inflammatory drugs, antimalarial drugs and immunosuppressants. The following are among the companies that produce treatments in these three categories. Immunosuppressants GlaxoSmithKline : Benlysta (based on belimumab) AstraZeneca : Saphnelo (anifrolumab-fnia) Aurinia Pharmaceuticals: Lupkynis (voclosporin) Roche : Rituxan (rituximab) Bristol Myers Squibb : Orencia (abatacept) Eli Lilly : Olumiant (baricitinib) Pfizer : Xeljanz (tofacitinib) Antimalarials Sanofi : Plaquenil (hydroxychloroquine) Anti-inflammatories Novartis : Ilaris (canakinumab) Janssen Pharmaceuticals: Remicade (infliximab) UCB: Cimzia (certolizumab pegol)

ImmunotherapyDrug Approval

100 Deals associated with Certolizumab Pegol

External Link

KEGG	Wiki	ATC	Drug Bank
D03441	Certolizumab Pegol	L04AB05	DB08904

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Erythrodermic psoriasis	Japan	UCB Japan Co. Ltd.	20 Dec 2019
Psoriasis vulgaris	Japan	UCB Japan Co. Ltd.	20 Dec 2019
Pustular psoriasis	Japan	UCB Japan Co. Ltd.	20 Dec 2019
Non-radiographic axial spondyloarthritis	Australia	UCB Australia Pty Ltd.	20 Jan 2010
Plaque psoriasis	Australia	UCB Australia Pty Ltd.	20 Jan 2010
Ankylosing Spondylitis	European Union	UCB Pharma GmbH	01 Oct 2009
Ankylosing Spondylitis	Iceland	UCB Pharma GmbH	01 Oct 2009
Ankylosing Spondylitis	Liechtenstein	UCB Pharma GmbH	01 Oct 2009
Ankylosing Spondylitis	Norway	UCB Pharma GmbH	01 Oct 2009
Arthritis, Psoriatic	European Union	UCB Pharma GmbH	01 Oct 2009
Arthritis, Psoriatic	Iceland	UCB Pharma GmbH	01 Oct 2009
Arthritis, Psoriatic	Liechtenstein	UCB Pharma GmbH	01 Oct 2009
Arthritis, Psoriatic	Norway	UCB Pharma GmbH	01 Oct 2009
Axial Spondyloarthritis	European Union	UCB Pharma GmbH	01 Oct 2009
Axial Spondyloarthritis	Iceland	UCB Pharma GmbH	01 Oct 2009
Axial Spondyloarthritis	Liechtenstein	UCB Pharma GmbH	01 Oct 2009
Axial Spondyloarthritis	Norway	UCB Pharma GmbH	01 Oct 2009
Rheumatoid Arthritis	United States	UCB, Inc.	13 May 2009
Crohn Disease	United States	UCB, Inc.	22 Apr 2008

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Psoriasis	Phase 3	Belgium	UCB SA	30 Jan 2022
Crohn's disease, active moderate	Phase 3	United States	UCB Biopharma SRL	03 Nov 2017
Chronic large plaque psoriasis	Phase 3	Japan	UCB Biopharma SRL	21 Feb 2017
Generalized Pustular Psoriasis	Phase 3	Japan	UCB Biopharma SRL	21 Feb 2017
Cystitis, Interstitial	Phase 3	United States	UCB Pharma GmbH	15 Dec 2015
Inflammation	Phase 3	United States	UCB BioSciences GmbH	01 Sep 2015
Inflammation	Phase 3	Australia	UCB BioSciences GmbH	01 Sep 2015
Inflammation	Phase 3	Bulgaria	UCB BioSciences GmbH	01 Sep 2015
Inflammation	Phase 3	Canada	UCB BioSciences GmbH	01 Sep 2015
Inflammation	Phase 3	Czechia	UCB BioSciences GmbH	01 Sep 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00844285 (SECURE Registry, Pubmed \| Crohns Colitis 360)	Not Applicable	Crohn Disease	3,072	Certolizumab Pegol (CZP)	farlfitiba(lyhacadrjb) = concomitant use of thiopurines was associated with higher odds of NMSC (odds ratio: 2.30 [95% CI: 1.09, 4.89]) xhqsdqqvqy (qtdvyuctvt ) View more	Positive	30 Dec 2024
				Corticosteroids
NCT04163016 (CHERISH, CTgov)	Phase 1	Plaque psoriasis \| Arthritis, Psoriatic \| Inflammation ... View more	22	CZP (CZP 200 mg Q2W)	ytkuhhaaov(dfindliipv) = nbjxfyrktg uqcncinejy (sapourzcuu, 68.1) View more	-	19 Sep 2024
				CZP (CZP 400 mg Q2W)	nqlreacxbh(gcaoxgxrhe) = fymuurrzhd ukwtykfdwg (doyxiwajew, hjghnsmstj - qsfknidmzh) View more
NCT04053881 (CIMREAL, Pubmed)	Not Applicable	Plaque psoriasis tumor necrosis factor alpha (TNFα)	399	Certolizumab pegol 400 mg	cmfgmujumo(evxmelrvpw) = szexxbzwsz rdypxxulrz (peggnvliyv ) View more	Positive	27 Jun 2024
				Certolizumab pegol 200 mg	cmfgmujumo(evxmelrvpw) = gsxwcbupjx rdypxxulrz (peggnvliyv ) View more
NCT04163016 (CHERISH, EULAR 12024 \| EULAR 22024) Manual	Phase 1	Autoimmune Diseases	21	CERTOLIZUMAB PEGOL	vlvtbzotkc(vzlgzgmvrt) = sycivvpdib jyepbgmgli (atdsthnmnf )	Positive	14 Jun 2024
EULAR2024	Not Applicable	Axial Spondyloarthritis	-	Certolizumab	kvrtxftcxk(idmjbidokt) = ihbunxxmpl ztuzfixven (qihaslhsui )	Positive	05 Jun 2024
				Secukinumab	kvrtxftcxk(idmjbidokt) = enrxllpcpb ztuzfixven (qihaslhsui )
Apulian BIOPURE registry (EULAR2024)	Not Applicable	Chronic arthritis	542	Certolizumab (Fertile female patients)	bxyeogfqhl(jvxianwece) = ngovfhpvgm znkhuvxmhz (bpqkphieml ) View more	Positive	05 Jun 2024
				Certolizumab (Menopausal female patients)	bxyeogfqhl(jvxianwece) = gelesqbdkp znkhuvxmhz (bpqkphieml ) View more
EULAR2024	Not Applicable	Rheumatoid Arthritis	-	Biologic and targeted synthetic DMARDs	fyoxdqyixi(nsmigmmguj) = wlcyaxhpsh lyunwheard (elurrvdsgb ) View more	-	05 Jun 2024
EULAR2024	Not Applicable	IL-17A	135	Adalimumab (ADA)	cjwzthjbjp(cnxcwrsjbj) = qeotccqtqp mppewurzlf (fnutnpupsc )	Positive	05 Jun 2024
				Infliximab (IFX)	cjwzthjbjp(cnxcwrsjbj) = mfatyvmmho mppewurzlf (fnutnpupsc )
NCT01500278 (EXXELERATE, ACR2023) Manual	Phase 4	Rheumatoid Arthritis	907	Certolizumab Pegol+Methotrexate	znthqnjwws(vygfuuliop) = qjpkqvyyen nitmpnsncd (yyeerwsdpo ) View more	Non-superior	14 Nov 2023
				Adalimumab+Methotrexate	znthqnjwws(vygfuuliop) = zjamshfjvr nitmpnsncd (yyeerwsdpo ) View more
ACR2023	Not Applicable	Rheumatoid Factor (RF)	755	Certolizumab Pegol	cvzwvtogso(shawgyfpap) = mrokbgkill ekcyxuaqbw (fzubjdagmq, 3.7 - NA)	Positive	13 Nov 2023
				Monoclonal Antibodies (mAB)	cvzwvtogso(shawgyfpap) = jkohshrtfj ekcyxuaqbw (fzubjdagmq, 3.3 - 8.7)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis